Insmed Announces Proposed Public Offering of Common Stock
MONMOUTH JUNCTION, N.J. (July 15, 2013) - Insmed Incorporated (Nasdaq CM: INSM) ("Insmed") announced today that it is offering $60 million of its common stock in a proposed underwritten public offering. All of the shares in the offering will be sold by Insmed.
The action to create more INSM shares also takes the hope of a buyout further off the table. Who is going to buy INSM at a higher price just to get a stack of cash??
Also, INSM management is saying that they are not expecting a better price for shares in the near future. Otherwise, they would have waited for that higher price before pulling the trigger.
Longs need to plan on a bit longer before their gamble has any potential for a payoff. It is the nature of biotech. The manufacturer of Arikace has some cash coming its way though.
I blush ...15% dilution = $9 + Kaching!!!-2 calls exactly as they played out - and Ive got another one for ya PHASE3 IN THE U.S Timmmberrrrr .terry_insm • Jun 17, 2013 11:44 AM "A POSSIBLE Dilution and POSSIBLE less than compelling data seems to have upset zippy(dorain) the clown ( mostly ignored)...these issues and those below should be in every investors Insmed DD...28 thumbs lol are nonsense from emotional (and immature) investors.
Exactly as I expected (and posted)... same old Insmed, same old crooks: shorts being given an exit by Insmed (as so many times before).
In my case I just GUESS (based on experience of being repeatedly shafted).
Bande: how come you seem to know? Do you (also) "just guess" (better than most folks here?) or does someone at the SFU get the tip offs? Curious... Insmed/insiders/VCs/etc don't seem to care how obvious their behavior is. the pattern is repeated over and over...
AWESOME! .. for people like me it will allow for a good entry point instead of having to wait for a pullback.
Arikace is better than tobi (because its is 1x a day rather than 2x showing same data) and it most likely will be employed more broadly in NTM lung infections.